Buy Mazdutide 6mg

Mazdutide (IBI362) combines GLP-1 receptor agonism for appetite suppression with glucagon receptor activation for increased thermogenesis and hepatic fat oxidation — the same dual-agonist concept that makes retatrutide more potent than semaglutide, without the GIP component. Phase 2 data in Chinese populations showed 14.5% body weight reduction at 9mg weekly, with strong visceral fat reduction and lipid improvements. The glucagon component is what differentiates dual agonists from pure GLP-1s: it activates brown adipose tissue, increases basal energy expenditure, and promotes hepatic fat clearance. For users who have plateaued on semaglutide or want more thermogenic activity than pure GLP-1 provides, Mazdutide represents the intermediate step toward triple-agonist territory.